| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| estradiol | beclin-1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Vagina[MeSHID:D014621] Osteoporosis Postmenopausal[MeSHID:D015663] Endometrium[MeSHID:D004717] Malignant neoplasm of prostate[MeSHID:D011471] Estrogen Effect[MeSHID:D004967] Ovarian Failure Premature[MeSHID:D016649] Pregnancy[MeSHID:D011247] Neoplasm Metastasis[MeSHID:D009362] Thromboembolism[MeSHID:D013923] Malignant neoplasm of breast[MeSHID:D001943] Postmenopause[MeSHID:D017698] Endometrial Hyperplasia[MeSHID:D004714] Uterus[MeSHID:D014599] Hypogonadism[MeSHID:D007006] Growth[MeSHID:D006128] Atrophic[MeSHID:D001284] Patient Discharge[MeSHID:D010351] Vulva[MeSHID:D014844] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational,vet_approved | binder |
| estradiol | neuronal acetylcholine receptor subunit alpha-4 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Vagina[MeSHID:D014621] Osteoporosis Postmenopausal[MeSHID:D015663] Endometrium[MeSHID:D004717] Malignant neoplasm of prostate[MeSHID:D011471] Estrogen Effect[MeSHID:D004967] Ovarian Failure Premature[MeSHID:D016649] Pregnancy[MeSHID:D011247] Neoplasm Metastasis[MeSHID:D009362] Thromboembolism[MeSHID:D013923] Malignant neoplasm of breast[MeSHID:D001943] Postmenopause[MeSHID:D017698] Endometrial Hyperplasia[MeSHID:D004714] Uterus[MeSHID:D014599] Hypogonadism[MeSHID:D007006] Growth[MeSHID:D006128] Atrophic[MeSHID:D001284] Patient Discharge[MeSHID:D010351] Vulva[MeSHID:D014844] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational,vet_approved | binder |
| estradiol | estrogen receptor | NA | Successful target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Vagina[MeSHID:D014621] Osteoporosis Postmenopausal[MeSHID:D015663] Endometrium[MeSHID:D004717] Malignant neoplasm of prostate[MeSHID:D011471] Estrogen Effect[MeSHID:D004967] Ovarian Failure Premature[MeSHID:D016649] Pregnancy[MeSHID:D011247] Neoplasm Metastasis[MeSHID:D009362] Thromboembolism[MeSHID:D013923] Malignant neoplasm of breast[MeSHID:D001943] Postmenopause[MeSHID:D017698] Endometrial Hyperplasia[MeSHID:D004714] Uterus[MeSHID:D014599] Hypogonadism[MeSHID:D007006] Growth[MeSHID:D006128] Atrophic[MeSHID:D001284] Patient Discharge[MeSHID:D010351] Vulva[MeSHID:D014844] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.19 | approved | agonist |
| estradiol | estrogen receptor alpha | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Vagina[MeSHID:D014621] Osteoporosis Postmenopausal[MeSHID:D015663] Endometrium[MeSHID:D004717] Malignant neoplasm of prostate[MeSHID:D011471] Estrogen Effect[MeSHID:D004967] Ovarian Failure Premature[MeSHID:D016649] Pregnancy[MeSHID:D011247] Neoplasm Metastasis[MeSHID:D009362] Thromboembolism[MeSHID:D013923] Malignant neoplasm of breast[MeSHID:D001943] Postmenopause[MeSHID:D017698] Endometrial Hyperplasia[MeSHID:D004714] Uterus[MeSHID:D014599] Hypogonadism[MeSHID:D007006] Growth[MeSHID:D006128] Atrophic[MeSHID:D001284] Patient Discharge[MeSHID:D010351] Vulva[MeSHID:D014844] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.19 | approved,investigational,vet_approved | agonist |
| estradiol | estrogen receptor | NA | Successful target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Vagina[MeSHID:D014621] Osteoporosis Postmenopausal[MeSHID:D015663] Endometrium[MeSHID:D004717] Malignant neoplasm of prostate[MeSHID:D011471] Estrogen Effect[MeSHID:D004967] Ovarian Failure Premature[MeSHID:D016649] Pregnancy[MeSHID:D011247] Neoplasm Metastasis[MeSHID:D009362] Thromboembolism[MeSHID:D013923] Malignant neoplasm of breast[MeSHID:D001943] Postmenopause[MeSHID:D017698] Endometrial Hyperplasia[MeSHID:D004714] Uterus[MeSHID:D014599] Hypogonadism[MeSHID:D007006] Growth[MeSHID:D006128] Atrophic[MeSHID:D001284] Patient Discharge[MeSHID:D010351] Vulva[MeSHID:D014844] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.19 | approved | unknown |
| estradiol | estrogen receptor beta | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Vagina[MeSHID:D014621] Osteoporosis Postmenopausal[MeSHID:D015663] Endometrium[MeSHID:D004717] Malignant neoplasm of prostate[MeSHID:D011471] Estrogen Effect[MeSHID:D004967] Ovarian Failure Premature[MeSHID:D016649] Pregnancy[MeSHID:D011247] Neoplasm Metastasis[MeSHID:D009362] Thromboembolism[MeSHID:D013923] Malignant neoplasm of breast[MeSHID:D001943] Postmenopause[MeSHID:D017698] Endometrial Hyperplasia[MeSHID:D004714] Uterus[MeSHID:D014599] Hypogonadism[MeSHID:D007006] Growth[MeSHID:D006128] Atrophic[MeSHID:D001284] Patient Discharge[MeSHID:D010351] Vulva[MeSHID:D014844] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.31 | approved,investigational,vet_approved | agonist |
| estradiol | g-protein coupled estrogen receptor 1 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Vagina[MeSHID:D014621] Osteoporosis Postmenopausal[MeSHID:D015663] Endometrium[MeSHID:D004717] Malignant neoplasm of prostate[MeSHID:D011471] Estrogen Effect[MeSHID:D004967] Ovarian Failure Premature[MeSHID:D016649] Pregnancy[MeSHID:D011247] Neoplasm Metastasis[MeSHID:D009362] Thromboembolism[MeSHID:D013923] Malignant neoplasm of breast[MeSHID:D001943] Postmenopause[MeSHID:D017698] Endometrial Hyperplasia[MeSHID:D004714] Uterus[MeSHID:D014599] Hypogonadism[MeSHID:D007006] Growth[MeSHID:D006128] Atrophic[MeSHID:D001284] Patient Discharge[MeSHID:D010351] Vulva[MeSHID:D014844] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
1.7 | approved,investigational,vet_approved | binder |
| estradiol | atp synthase subunit a | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Vagina[MeSHID:D014621] Osteoporosis Postmenopausal[MeSHID:D015663] Endometrium[MeSHID:D004717] Malignant neoplasm of prostate[MeSHID:D011471] Estrogen Effect[MeSHID:D004967] Ovarian Failure Premature[MeSHID:D016649] Pregnancy[MeSHID:D011247] Neoplasm Metastasis[MeSHID:D009362] Thromboembolism[MeSHID:D013923] Malignant neoplasm of breast[MeSHID:D001943] Postmenopause[MeSHID:D017698] Endometrial Hyperplasia[MeSHID:D004714] Uterus[MeSHID:D014599] Hypogonadism[MeSHID:D007006] Growth[MeSHID:D006128] Atrophic[MeSHID:D001284] Patient Discharge[MeSHID:D010351] Vulva[MeSHID:D014844] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational,vet_approved | inhibitor |
| estradiol | nuclear receptor subfamily 1 group i member 2 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Vagina[MeSHID:D014621] Osteoporosis Postmenopausal[MeSHID:D015663] Endometrium[MeSHID:D004717] Malignant neoplasm of prostate[MeSHID:D011471] Estrogen Effect[MeSHID:D004967] Ovarian Failure Premature[MeSHID:D016649] Pregnancy[MeSHID:D011247] Neoplasm Metastasis[MeSHID:D009362] Thromboembolism[MeSHID:D013923] Malignant neoplasm of breast[MeSHID:D001943] Postmenopause[MeSHID:D017698] Endometrial Hyperplasia[MeSHID:D004714] Uterus[MeSHID:D014599] Hypogonadism[MeSHID:D007006] Growth[MeSHID:D006128] Atrophic[MeSHID:D001284] Patient Discharge[MeSHID:D010351] Vulva[MeSHID:D014844] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational,vet_approved | binder |
| click here to return to the previous page | ||||||||